8,752 results on '"Stephen, A."'
Search Results
2. PD05-08 ADDRESSING RACIAL DISPARITIES IN PROSTATE CANCER PATHOLOGY PREDICTION MODELS: EXTERNAL VALIDATION AND COMPARISON OF FOUR MODELS OF PATHOLOGICAL OUTCOME PREDICTION BEFORE RADICAL PROSTATECTOMY
3. PD25-12 TWO BLADDER-CENTRIC PHENOTYPIC SUBGROUPS WITHIN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME PATIENTS WITH LOW BLADDER CAPACITY
4. PD20-07 ONCOLOGIC OUTCOMES IN PATIENTS WITH VARIANT HISTOLOGIES OF UPPER TRACT UROTHELIAL CANCER: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT
5. MP10-15 USING ARTIFICIAL INTELLIGENCE TO CHARACTERIZE BODY COMPOSITION IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY
6. PD25-01 SMALL FIBER POLYNEUROPATHY IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: AN IMPORTANT FEATURE OF THE NON-BLADDER-CENTRIC SYSTEMIC PAIN PHENOTYPE
7. PD03-05 DOES INSULIN RESISTANCE CREATE A BIGGER PROSTATE? RESULTS FROM THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
8. MP24-05 NARRATIVE CONTENT OF PATIENTS DURING MULTIDISCIPLINARY CONSULTATIONS FOR CLINICALLY LOCALIZED PROSTATE CANCER
9. PD04-08 MIRABEGRON AS PART OF COMBINATION THERAPY FOR TREATMENT OF REFRACTORY NEUROGENIC BLADDER IN PEDIATRIC PATIENTS WITH SPINA BIFIDA
10. MP21-08 CAN VIDEOURODYNAMICS SHAPE MANAGEMENT IN REFRACTORY PEDIATRIC LOWER URINARY TRACT DYSFUNCTION?
11. MP67-19 IS THERE ANY EVIDENCE TO JUSTIFY MECHANICAL BOWEL PREPARATION PRIOR TO NEPHRECTOMY IN THE MINIMALLY INVASIVE ERA?
12. MP57-11 THE COST OF REUSABLE CYSTOSCOPY: A MICROCOSTING EVALUATION AT A U.S. ACADEMIC MEDICAL CENTER
13. PD61-01 SPECIALTY BIAS IN REPORTING OF ADVANTAGES AND DISADVANTAGES OF TREATMENT OPTIONS IN CONSULTATIONS FOR EARLY STAGE PROSTATE CANCER
14. MP12-13 WHAT WOULD YOU DO IF IT WERE YOU, DOC?: PATIENT AND PHYSICIAN PERSPECTIVES ON WHY PROSTATE CANCER PATIENTS SEEK “PERSONAL ADVICE” FROM PROVIDERS AND HOW PHYSICIANS RESPOND
15. MP54-05 DOES RACE, ETHNICITY, AND/OR GENDER OF UROLOGY PROVIDERS HAVE AN IMPACT ON PRESS-GANEY SCORES?
16. MP12-12 PHYSICIAN PREFERENCES REGARDING COMMUNICATION OF LIFE EXPECTANCY IN PROSTATE CANCER TREATMENT CONSULTATIONS
17. PD17-12 IS THERE A ROLE FOR C-11 PET-CT IN MEN WITH BIOCHEMICAL PROGRESSION OF PROSTATE CANCER AND NEGATIVE PSMA PET-CT?
18. MP02-05 NEXT STOP ON THE ERAS TOUR: REDUCING POST OPERATIVE PAIN AND OPIOID USAGE THROUGH AN ENHANCED RECOVERY PATHWAY FOR PERCUTANEOUS NEPHROLITHOTOMY
19. PD34-06 CHANGES IN BODY COMPOSITION FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY
20. PD34-03 INTRAOPERATIVE TRANEXAMIC ACID IN RADICAL CYSTECTOMY: IMPACT ON BLEEDING, THROMBOEMBOLISM, AND CANCER-SPECIFIC SURVIVAL
21. MP03-08 RATES OF SURGICAL MANAGEMENT AND REPEAT PROCEDURES FOR STRESS URINARY INCONTINENCE FOLLOWING RADICAL PROSTATECTOMY IN THE UNITED STATES
22. MP26-03 KIDNEY STONE PREVENTION: CAN AI SERVE AS YOUR DIETARY GUIDE?*
23. PD54-05 VOIDING DYSFUNCTION AMONG OLDER ADULTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: INCIDENCE AND PREDICTORS OF TREATMENT FOR OVERACTIVE BLADDER
24. PD63-01 EVALUATING THE SAFETY AND EFFECTIVENESS OF UROMUNE® BACTERIAL VACCINE OVER A 9-YEAR PERIOD IN THE UK: A STUDY ON MANAGING RECURRENT URINARY TRACT INFECTIONS IN MEN AND WOMEN IN THE INITIAL COHORT
25. MP12-16 NATIONAL TRENDS IN SAME DAY DISCHARGE FOR RADICAL PROSTATECTOMY: AN EVOLUTION IN PRACTICE PATTERNS
26. MP56-13 HOSPITAL CASE VOLUME DISTRIBUTION AND OUTCOMES FOR PATIENTS UNDERGOING RADICAL NEPHRECTOMY WITH IVC OR INTRA-ATRIAL TUMOR THROMBUS: DATA FROM THE NATIONAL INPATIENT SAMPLE
27. PD25-06 A SIGNIFICANT PROPORTION OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME PATIENTS HAVE SUSTAINED SYMPTOM IMPROVEMENT FOLLOWING THERAPEUTIC HYDRODISTENSION
28. MP56-09 MICROWAVE ABLATION VS. ACTIVE SURVEILLANCE FOR CT1A SMALL RENAL MASSES
29. MP43-08 RISK OF OCCUPATIONAL HEARING LOSS DURING COMMON ENDOUROLOGIC PROCEDURES: PCNL, URS, HOLEP, AND SWL
30. MP10-07 COMPREHENSIVE EVALUATION OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PRIMARY TUMOR: RADIOGRAPHIC AND RADIOMIC FEATURES PREDICT PATHOLOGIC RESPONSE IN PRIMARY TUMOR
31. MP24-03 DEVELOPMENT AND VALIDATION OF A NATURAL LANGUAGE PROCESSING SYSTEM TO IDENTIFY INFORMATION ON KEY TRADEOFFS IN PROSTATE CANCER TREATMENT CONSULTATIONS
32. PD30-03 PREDICTING RESPONSE TO INTRAVESICAL BCG IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER USING AN ARTIFICIAL INTELLIGENCE-POWERED PATHOLOGY ASSAY: DEVELOPMENT AND VALIDATION IN AN INTERNATIONAL 12 CENTER COHORT
33. MP24-01 INTEGRATING NATURAL LANGUAGE PROCESSING WITH CHATGPT TO IMPROVE QUALITY OF ARTIFICIAL INTELLIGENCE SUMMARIES OF PROSTATE CANCER CONSULTATIONS
34. MP33-05 SINGLE-USE CYSTOSCOPES OFFERS FASTER TIME-TO-SCOPE WITH EQUIVALENT PERCEIVED FUNCTIONALITY VS REUSABLE SCOPES IN THE INPATIENT SETTING
35. MP77-18 PREDICTORS OF PELVIC RECURRENCE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS
36. PD18-01 GENOMIC CHARACTERIZATION OF RECURRENT URCC TUMORS
37. PD34-08 A PROSPECTIVE RANDOMIZED PHASE 3 TRIAL EVALUATING BENEFITS OF PERISTOMAL MESH PLACEMENT AT THE TIME OF RADICAL CYSTECTOMY AND ILEAL CONDUIT FORMATION
38. PD07-01 BLADDER SHAPE DOES NOT CORRELATE WITH UPPER AND LOWER URINARY TRACT FINDINGS IN CHILDREN WITH SPINA BIFIDA
39. MP07-19 ARTIFICIAL INTELLIGENCE (AI) FOR MEASURING RENAL CALCULUS VOLUME: INITIAL SINGLE-CENTER DESCRIPTION OF SEQUENTIAL AI-ENHANCED ULTRA-LOW DOSE CT’S
40. PD62-05 PATIENT PERCEPTIONS OF STANDARDIZED RISK LANGUAGE USED IN AMERICAN COLLEGE OF RADIOLOGY PROSTATE MRI PIRADS SCORES
41. MP56-17 LONG-TERM FOLLOW-UP AFTER NEPHRECTOMY FOR RENAL ONCOCYTOMA: RISK AND PATTERNS OF SYNCHRONOUS AND METACHRONOUS RENAL TUMOR
42. PD04-03 DEEP LEARNING OF VIDEOURODYNAMICS TO PREDICT INCIDENT HYDRONEPHROSIS IN PATIENTS WITH SPINA BIFIDA
43. MP07-09 AUTOMATED SURGICAL STEP RECOGNITION IN TRANSURETHRAL BLADDER TUMOR RESECTION USING ARTIFICIAL INTELLIGENCE: TRANSFER LEARNING ACROSS SURGICAL MODALITIES
44. PD14-04 BLADDER CANCER CTC-PDX MODEL SYSTEMS PLATFORM FOR DISCOVERING DRUGGABLE MOLECULAR PATHWAYS TO OVERCOME CISPLATIN-BASED THERAPY RESISTANCE
45. PD05-04 INVESTIGATING THE ROLE OF ACCESS TO QUALITY CARE FOR MUSCLE-INVASIVE BLADDER CANCER IN THE DISPARATE OUTCOMES FOR SOCIODEMOGRAPHICALLY DISADVANTAGED PATIENTS IN THE STATE OF KENTUCKY
46. MP35-07 RACIAL DIFFERENCES IN BLADDER CANCER MORTALITY ADJUSTING FOR SOCIODEMOGRAPHIC DISPARITIES IN A STATEWIDE CANCER REGISTRY
47. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
48. MP45-08 THE IMPACT OF KIDNEY STONE DISEASE ON QUALITY OF LIFE IN HIGH-RISK STONE FORMERS
49. MP34-01 BASELINE PROSTATE-SPECIFIC ANTIGEN SCREENING VALUES IN TRANSGENDER WOMEN ON GENDER-AFFIRMING HORMONE THERAPY: A NATIONAL COHORT STUDY
50. MP07-04 INITIAL EXPERIENCE WITH A FULLY INTEGRATED ARTIFICIAL INTELLIGENCE PLATFORM DURING MINIMALLY INVASIVE SURGERY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.